| Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers JJ Carlson, SD Sullivan, LP Garrison, PJ Neumann, DL Veenstra Health policy 96 (3), 179-190, 2010 | 364 | 2010 |
| The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis JJ Carlson, JA Roth Breast cancer research and treatment 141, 13-22, 2013 | 256 | 2013 |
| Cost effectiveness of pharmacogenomics: a critical and systematic review WB Wong, JJ Carlson, R Thariani, DL Veenstra Pharmacoeconomics 28, 1001-1013, 2010 | 130 | 2010 |
| Performance-based risk-sharing arrangements: an updated international review JJ Carlson, S Chen, LP Garrison Pharmacoeconomics 35, 1063-1072, 2017 | 106 | 2017 |
| Predicting low accrual in the National Cancer Institute’s Cooperative Group clinical trials CS Bennette, SD Ramsey, CL McDermott, JJ Carlson, A Basu, ... Journal of the National Cancer Institute 108 (2), djv324, 2016 | 97 | 2016 |
| Prognostic Role of ERCC1 in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis JA Roth, JJ Carlson Clinical lung cancer 12 (6), 393-401, 2011 | 93 | 2011 |
| The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR‐tyrosine kinase inhibitor therapy in non–small‐cell lung cancer JJ Carlson, LP Garrison, SD Ramsey, DL Veenstra Value in Health 12 (1), 20-27, 2009 | 91 | 2009 |
| Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis EW Radue, WH Stuart, PA Calabresi, C Confavreux, SL Galetta, ... Journal of the neurological sciences 292 (1-2), 28-35, 2010 | 84 | 2010 |
| Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC) JJ Carlson, C Reyes, N Oestreicher, D Lubeck, SD Ramsey, DL Veenstra Lung cancer 61 (3), 405-415, 2008 | 80 | 2008 |
| Private sector risk-sharing agreements in the United States: trends, barriers, and prospects PJ Neumann, SD Sullivan, K Westrich, RW Dubois Am. J. Manag. Care 21 (9), 632-640, 2015 | 74 | 2015 |
| Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers JJ Carlson, KS Gries, K Yeung, SD Sullivan, LP Garrison Applied health economics and health policy 12, 231-238, 2014 | 71 | 2014 |
| Cost utility of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease M Zimmermann, SJ Lubinga, R Banken, D Rind, G Cramer, PG Synnott, ... Value in Health 22 (2), 161-167, 2019 | 64 | 2019 |
| Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals J Carlson, LP Garrison Jr, SD Sullivan Journal of Managed Care Pharmacy 15 (8), 683-687, 2009 | 63 | 2009 |
| Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis M Sonya Kahn, D Rind, R Chapman, V Kumar, S Kahn, J Carlson J Drugs Dermatol 17 (7), 750-756, 2018 | 59 | 2018 |
| Economic analyses of human genetics services: a systematic review JJ Carlson, NB Henrikson, DL Veenstra, SD Ramsey Genetics in Medicine 7 (8), 519-523, 2005 | 59 | 2005 |
| Cost-effectiveness of drugs to treat relapsed/refractory multiple myeloma in the United States JJ Carlson, GF Guzauskas, RH Chapman, PG Synnott, S Liu, ET Russo, ... Journal of managed care & specialty pharmacy 24 (1), 29-38, 2018 | 55 | 2018 |
| An evaluation of the potential cost‐effectiveness of non‐invasive testing strategies in the diagnosis of significant liver fibrosis JJ Carlson, KV Kowdley, SD Sullivan, SD Ramsey, DL Veenstra Journal of gastroenterology and hepatology 24 (5), 786-791, 2009 | 51 | 2009 |
| Disease-modifying therapies for relapsing–remitting and primary progressive multiple sclerosis: a cost-utility analysis M Zimmermann, E Brouwer, JA Tice, M Seidner, AM Loos, S Liu, ... CNS drugs 32, 1145-1157, 2018 | 50 | 2018 |
| Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests SD Ramsey, DL Veenstra, LP Garrison Jr, R Carlson, P Billings, J Carlson, ... Am J Manag Care 12 (4), 197-202, 2006 | 49 | 2006 |
| Health years in total: a new health objective function for cost-effectiveness analysis A Basu, J Carlson, D Veenstra Value in Health 23 (1), 96-103, 2020 | 48 | 2020 |
